Related Experiment Videos
Ketoprofen (Orudis) in ankylosing spondylitis
The New Zealand Medical Journal
|May 14, 1975
Summary
Phenylbutazone was preferred by patients with ankylosing spondylitis, but ketoprofen showed no objective deterioration, suggesting it as a potential alternative treatment.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Ankylosing spondylitis is a chronic inflammatory condition.
- Phenylbutazone is a common treatment for ankylosing spondylitis.
Purpose of the Study:
- To compare the efficacy and patient preference of ketoprofen versus phenylbutazone in ankylosing spondylitis patients.
Main Methods:
- A double-blind, cross-over study design.
- 14 patients with ankylosing spondylitis participated.
- Ketoprofen (Orudis) was compared against phenylbutazone.
Main Results:
- Patients showed a significant preference for phenylbutazone.
- Phenylbutazone led to greater improvement in Erythrocyte Sedimentation Rate (ESR).
- Ketoprofen did not result in objective or laboratory deterioration.
Conclusions:
- Ketoprofen may serve as a viable alternative to phenylbutazone for treating ankylosing spondylitis.
- Further research is warranted to confirm ketoprofen's long-term efficacy and safety in spondylitic disease.